A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Tonix Pharmaceuticals Holding Corp.
TNXP
$84M
Mkt Cap
$9.88
-6.97%
Tonix Pharmaceuticals Holding Corp. (TNXP) has a 5-year average return on invested capital (ROIC) of -96.9%. This is below average and may indicate limited pricing power.
Tonix Pharmaceuticals Holding Corp. (TNXP) has a market capitalization of $84M. It is classified as a small-cap stock.
Tonix Pharmaceuticals Holding Corp. (TNXP) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 16.36%.
Tonix Pharmaceuticals Holding Corp. (TNXP) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Tonix Pharmaceuticals Holding Corp. (TNXP) generated $-103 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Tonix Pharmaceuticals Holding Corp. (TNXP) has a debt-to-equity ratio of 0.04. This indicates a conservatively financed balance sheet.
ITEM 1 – BUSINESS This Annual Report on Form 10-K (including the section regarding Management’s Discussion and Analysis of Financial Condition and Results of Operations) contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this Annual Report on Form 10-K. Additionally, statements concerning future matters are forward-looking statements. Although forward-looking statements in this Annual Report on Form 10-K reflect the good faith judgment of our Management, such statements can only be based on facts and factors currently known by us.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 10M | - | - | - |
| Net Income | -124M | -124M | - | -117M | -48M | -28M |
| EPS | $-14.57 | $-14.57 | $-5,121.40 | $-20,208.60 | $-9,370.74 | $-906.95 |
| Free Cash Flow | -103M | -103M | -61M | -110M | -43M | -23M |
| ROIC | -204.9% | -62.2% | - | -73.1% | -125.9% | -126.6% |
| Gross Margin | - | - | 23.1% | - | - | - |
| Debt/Equity | 0.04 | 0.04 | 0.06 | 0.09 | 0.17 | 0.00 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | - | - |
| Operating Income | -126M | -126M | -137M | -118M | -48M | -28M |
| Operating Margin | 0.0% | - | -1354.3% | - | - | - |
| ROE | -50.6% | -64.5% | - | -74.6% | -125.9% | -129.6% |
| Shares Outstanding | 9M | 9M | 0M | 0M | 0M | 0M |
| Metric | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 10M | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 23.1% | N/A | N/A |
| R&D | 584K | 1.2M | 2.6M | 4.6M | 19M | 36M | 87M | 40M | 44M | 44M |
| SG&A | 1.3M | 2.2M | 4.1M | 6.2M | 9.0M | 13M | 35M | 40M | 88M | 88M |
| EBIT | -1.9M | -3.4M | -6.7M | -11M | -28M | -48M | -118M | -137M | -126M | -126M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1354.3% | N/A | 0.0% |
| Net Income | -2.0M | -3.5M | -9.4M | -11M | -28M | -48M | -117M | N/A | -124M | -124M |
| Net Margin | 0.0% | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 62K | 965K | 669K | 669K |
| Returns on Capital | ||||||||||
| ROIC | N/M | N/M | N/M | -98.5% | -126.6% | -125.9% | -73.1% | N/A | -62.2% | N/M |
| ROE | N/A | 264.0% | -985.4% | -291.4% | -129.6% | -125.9% | -74.6% | N/A | -64.5% | -50.6% |
| ROA | -1067.4% | -1138.7% | -743.4% | -200.6% | -114.4% | -111.0% | -61.4% | N/A | -56.4% | -44.7% |
| Cash Flow | ||||||||||
| Op. Cash Flow | -1.2M | -2.6M | -10M | -8.5M | -23M | -43M | -102M | -61M | -100M | -100M |
| Free Cash Flow | -1.3M | -2.6M | -10M | -8.5M | -23M | -43M | -110M | -61M | -103M | -103M |
| Owner Earnings | -1.4M | -3.1M | -11M | -10M | -26M | -47M | -116M | -69M | -108M | -108M |
| CapEx | 34K | 3K | 36K | 15K | 319K | 118K | 7.9M | 120K | 3.4M | 3.4M |
| Maint. CapEx | 4K | 17K | 32K | 48K | 84K | 161K | 4.3M | 3.4M | 1.9M | 1.9M |
| Growth CapEx | 30K | 0 | 4K | 0 | 235K | 0 | 3.6M | 0 | 1.4M | 1.4M |
| D&A | 4K | 17K | 32K | 48K | 84K | 161K | 4.3M | 3.4M | 1.9M | 1.9M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 14M | 0 | 14M | 14M |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% | 0.0% | 16.4% |
| Stock-Based Comp | 140K | 436K | 865K | 1.7M | 3.1M | 4.4M | 9.3M | 4.8M | 6.0M | 6.0M |
| Debt Repayment | 0 | 0 | 150K | 150K | 0 | 0 | 0 | 2.4M | 9.7M | 9.7M |
| Balance Sheet | ||||||||||
| Net Debt | -15K | 2.0M | -1.5M | -6.7M | -38M | N/A | -15M | -91M | -197M | -197M |
| Cash & Equiv. | 65K | 41K | 1.8M | 8.2M | 38M | 19M | 25M | 99M | 208M | 208M |
| Long-Term Debt | 0 | 1.9M | 0 | 1.0M | 0 | N/A | 6.6M | 4.7M | 9.7M | 9.7M |
| Debt/Equity | -0.29 | -0.85 | 0.33 | 0.23 | 0.00 | 0.17 | 0.09 | 0.06 | 0.04 | 0.04 |
| Interest Coverage | -53.9 | -36.9 | -2111.6 | -2722.0 | -691.4 | -445.9 | -1345.2 | -110.8 | -1412.4 | -1412.4 |
| Equity | -175K | -2.5M | 959K | 6.5M | 36M | 40M | 106M | 140M | 245M | 245M |
| Total Assets | 184K | 425K | 2.1M | 8.7M | 40M | 47M | 154M | 163M | 277M | 277M |
| Total Liabilities | 359K | 2.9M | 1.2M | 2.2M | 3.4M | 6.8M | 49M | 23M | 32M | 32M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | 120K | 9.7M | 120K | 120K | 120K |
| Retained Earnings | N/A | N/A | N/A | -27M | -54M | -102M | -601M | -731M | -855M | -855M |
| Working Capital | -252K | -782K | 872K | 6.4M | 36M | 40M | 29M | 101M | 198M | 198M |
| Current Assets | 89K | 144K | 2.0M | 8.6M | 39M | 46M | 48M | 119M | 229M | 229M |
| Current Liabilities | 340K | 925K | 1.1M | 2.2M | 3.4M | 6.6M | 19M | 18M | 31M | 31M |
| Per Share Data | ||||||||||
| EPS | -49.11 | -884.03 | -9,135.00 | -551.70 | -906.95 | -9,370.74 | -20,208.60 | -5,121.40 | -14.57 | -14.57 |
| Owner EPS | -34.44 | -787.35 | -10,730.33 | -521.20 | -854.27 | -9,180.42 | -20,019.96 | -457.05 | -12.66 | -12.66 |
| Book Value | -4.38 | -625.19 | 927.03 | 330.09 | 1,185.32 | 7,851.27 | 18,280.04 | 922.77 | 28.80 | 28.80 |
| Cash Flow/Share | -30.84 | -671.95 | -9,863.58 | -431.72 | -750.10 | -8,293.15 | -17,669.93 | -402.84 | -11.73 | -14.34 |
| Dividends/Share | 0.00 | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.2M | 8.5M | 8.5M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.7 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 95.0 | 26.4 | 1.7 | 3.0 | N/A | N/A | N/A | 0.3 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | -11.2% | -5.0% | -37.5% | -35.6% | N/A | N/A | N/A | -122.7% |
| Market Cap | 0 | N/A | 91M | 172M | 62M | 120M | 0 | 0 | 0 | 84M |
| Avg. Price | 0.00 | N/A | 10,220,800,000.00 | 4,150,222,222.22 | 6,983,241,434.26 | 4,475,961,904.76 | 0.00 | 0.00 | 0.00 | 9.88 |
| Year-End Price | 0.00 | N/A | 5,888,000,000.00 | 6,828,800,000.00 | 3,961,600,000.00 | 4,563,200,000.00 | 0.00 | 0.00 | 0.00 | 9.88 |
Tonix Pharmaceuticals Holding Corp. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 23.1%. Total shareholder yield (buybacks) is 16.4%.
Tonix Pharmaceuticals Holding Corp. (TNXP) reported earnings per share (EPS) of $-14.57 in its most recent fiscal year.
Tonix Pharmaceuticals Holding Corp. (TNXP) has a return on equity (ROE) of -64.5%. A negative ROE may indicate losses or negative equity.
Tonix Pharmaceuticals Holding Corp. (TNXP) has a 5-year average gross margin of 23.1%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 9 years of financial data for Tonix Pharmaceuticals Holding Corp. (TNXP), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Tonix Pharmaceuticals Holding Corp. (TNXP) has a book value per share of $28.80, based on its most recent annual SEC filing.